Literature DB >> 22579767

Development of a rapid, microplate-based kinetic assay for measuring adenosine deaminase activity in body fluids.

Jun Lu1, David G Grenache.   

Abstract

BACKGROUND: Adenosine deaminase (ADA) catalyzes the deamination of adenosine to inosine. The activity of ADA in body fluids has clinical utility in the assessment of suspected tuberculosis.
METHODS: The conversion of adenosine to inosine was monitored in 96-well microplates as a continuous decrease at 265 nm for 15 min at ambient temperature. Analytical precision, sensitivity, linearity, accuracy, and enzyme stability were validated. Reference intervals were established from >120 tuberculosis-negative pleural, peritoneal, and cerebrospinal fluid samples.
RESULTS: The molar extinction coefficients of adenosine and inosine at 265 nm were 12,715 and 4,918 l/mol.cm and their difference was used to calculate ADA activity. Maximum within-day imprecision was <11% and maximum total precision was <19%. Analytical sensitivity was 0.5 U/l and the assay was linear to 40 U/l. ADA recovery was 96-110% over an activity range of 11.7-25.3 U/l. ADA was stable for 1, 7 and 30 days at ~25 °C, 4-8 °C, and -20 °C storage, respectively. Upper reference limits were 9.4, 7.3, and 1.5 U/l for pleural, peritoneal, and cerebrospinal fluid, respectively.
CONCLUSIONS: The microplate-based kinetic ADA assay has favorable performance characteristics. This method eliminates the need for assay calibration and allows 96 samples to be tested simultaneously.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22579767     DOI: 10.1016/j.cca.2012.05.001

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  1 in total

1.  Development of Adenosine Deaminase-Specific IgY Antibodies: Diagnostic and Inhibitory Application.

Authors:  Agnieszka Łupicka-Słowik; Mateusz Psurski; Renata Grzywa; Kamila Bobrek; Patrycja Smok; Maciej Walczak; Andrzej Gaweł; Tadeusz Stefaniak; Józef Oleksyszyn; Marcin Sieńczyk
Journal:  Appl Biochem Biotechnol       Date:  2017-10-17       Impact factor: 2.926

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.